Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery. This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.
Checked against the public recordLast updated Apr 17, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Device Feasibility
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Stanford University
- Interventions being studied
- Radiation: Stereotactic Body Radiation Therapy (SBRT); Radiation: Computed Tomography (CT); Device: Cyberknife; Device: Trilogy; Device: True Beam; Drug: Iohexol; Drug: Iodixanol
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
INCLUSION CRITERIA * Either: * Established primary lung cancer/ cancer metastatic to lung, OR * Lesion suspicious for malignancy in lung, according to the following criteria: * Histopathologically confirmed lung cancer or cancer metastatic to lung, OR * Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR * Known metastatic cancer, with metastases to the lung based on imaging * Age \> 18 years old * Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV) * No prior surgery, chemotherapy, or radiation for the current lung tumor EXCLUSION CRITERIA * Prior radiotherapy to thorax * Iodine allergy * Contraindication to receiving radiotherapy, unless undergoing surgery * Pregnant
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University School of MedicineStanford, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 17, 2018. Always confirm current availability with the study team.